These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11061214)

  • 1. (-)Deprenyl (Selegiline): past, present and future.
    Knoll J
    Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
    Knoll J
    Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
    Miklya I
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
    Miklya I
    Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
    Knoll J; Miklya I
    Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
    Knoll J
    Pharmacol Toxicol; 1992 May; 70(5 Pt 1):317-21. PubMed ID: 1608919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
    Knoll J; Miklya I
    Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy.
    Löscher W; Hönack D
    J Pharmacol Exp Ther; 1995 Jul; 274(1):307-14. PubMed ID: 7616414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
    Miklya I; Knoll B; Knoll J
    Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.
    Knoll J; Miklya I
    Life Sci; 1995; 56(8):611-20. PubMed ID: 7869839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.